Slingshot members are tracking this event:

Gilead Announces CHMP Adopts Positive Opinion on Duscovy for Treatment of HIV

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details The Committee for Medicinal Products for Human Use (CHMP)  adopted a positive opinion on Gileads MAA for fixed dose combination Duscovy (emtricitabine/tenofovir alafenamide) for HIV.  The European Commission will now review the MAA with the recommendation from CHMP.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 26, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Chmp, Positive Opinion, Duscovy, Hiv, Tenofovir Alafenamide, Emtricitabine